Opinion/decision on a Paediatric investigation plan (PIP): Praluent, Alirocumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Endocrinology-Gynaecology-Fertility-Metabolism, PIP number: P/0550/2021

Opinion/decision on a Paediatric investigation plan (PIP): Rozlytrek, Entrectinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0351/2021

Opinion/decision on a Paediatric investigation plan (PIP): Vitrakvi, Larotrectinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0487/2021

Opinion/decision on a Paediatric investigation plan (PIP): Xalkori, crizotinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0036/2021

EMEA-002501-PIP01-18-M03

EMEA-001835-PIP01-15-M05

Opinion/decision on a Paediatric investigation plan (PIP): VeraSeal, human fibrinogen,human thrombin, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Other, PIP number: P/0052/2021

EMEA-002934-PIP01-20

Opinion/decision on a Paediatric investigation plan (PIP): Lenvima, Lenvatinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0280/2022

Opinion/decision on a Paediatric investigation plan (PIP): Upstaza, Eladocagene exuparvovec, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0075/2023